DeepUll, a Barcelona, Spain-based medical diagnostics company, raised €13M in Series B funding.
The round was led by Innvierte, with participation from Kurma Partners, Alta Life Sciences, UI Investissement, and Axis Participaciones Empresariales.
The company intends to use the funds to progress the development of its sepsis recognition platform towards the market.
Founded by Jordi Carrera and Rafel Bru who previously co-founded STAT-Dx, which was acquired by Qiagen in 2018, DeepUll is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. The company’s sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It will be a desktop system with end-to-end automation with the aim to be placed in any clinical setting.
FinSMEs
20/10/2022